Dabrafenib (GSK2118436)

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.

Price Stock Quantity  
USD 180 In stock
USD 90 In stock
USD 130 In stock
USD 170 In stock
USD 270 In stock
USD 400 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Dabrafenib (GSK2118436) Chemical Structure

Dabrafenib (GSK2118436) Chemical Structure
Molecular Weight: 519.56

Validation & Quality Control

Customer Product Validation(4)

Quality Control & MSDS

Related Compound Libraries

Dabrafenib (GSK2118436) is available in the following compound libraries:

Raf Inhibitors with Unique Features

  • Pan Raf Inhibitor

    AZ 628 Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.

  • Most Potent Raf Inhibitor

    PF-04880594 C-Raf, IC50=0.39 nM; B-Raf, IC50=0.19 nM.

  • FDA-approved Raf Inhibitor

    Sorafenib Tosylate Approved by FDA for advanced renal cancer。

  • Newest Raf Inhibitor

    TAK-632 Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

Product Information

  • Compare Raf Inhibitors
    Compare Raf Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.
Targets B-Raf (V600E) [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
C-Raf [1]
(Cell-free assay)
IC50 0.8 nM 3.2 nM 5.0 nM
In vitro Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-RafV600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-RafV600E. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MkXGT4lv[XOnIFHzd4F6NV;oVWN{UW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGhqeyC2YXfn[YQhSi2UYX[gWlYxOEVibYX0ZY51KGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgZ4VtdHNiY3:t[ZhxemW|c3nu[{BETEN|NzDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCkaX;0bY56dGG2ZXStUWVMKHC{b4TlbY4heGixc4Doc5J6dGG2aX;uJIJ6KEGucHjhV4Nz\WWwIHHzd4F6KHerdHigTWM2OCCxZjCwMlAxODdizszNMViyOFkxODZ5Mx?=
SK-MEL-28MkjpT4lv[XOnIFHzd4F6NIj0cY4yKGh?MX\Jcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCVSz3NSWwuOjhiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gSXJMKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFQh|ryPMkPXNlQ6ODB4N{O=
HepG2NVvsdHpSU2mwYYPlJGF{e2G7MUHJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCHUlugdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjByNDFOwG0>MUCyOFkxODZ5Mx?=
COLO205NIrPdlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9{MEWgZ4VtdCCycn;sbYZmemG2aX;uJJdqfGhiSVO1NEBw\iByLkCwO{DPxE1?NYntTWhGOjR7MEC2O|M>
HepG2NGTidm5HfW6ldHnvckBCe3OjeR?=Mnn6OFUhdWmwMlPCSG1UVw>?NIT0V5ZKdmirYnn0bY9vKG:oIFHsb|UhcW5iVFfGMYJmfGFvc4TpcZVt[XSnZDDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCVbXHkNkBxcG:|cHjvdplt[XSrb36geJJm[XSnZDDmc5IhPDVibXnud{BxemmxcjD0c{BVT0ZvYnX0ZUB{fGmvdXzheIlwdiCvZXHzeZJm\CCjZoTldkA3OCCvaX7zJIJ6KG:meYPz[Zkh[myxdDDzZ4FvdmW{IHHuZYx6e2m|IIfpeIghUUN3MDDv[kA{NjdizszNNFL3b2EzPDlyME[3Ny=>
HFFMonBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFKwbXkyOCEQvF2=NFjuTGU4OiCqMVnEUXNQNUG4c4lXUW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKG:oIHj1cYFvKEiIRjDj[YxteyCqYYLic5Jqdmdid3ns[EB1gXCnIFKtVoFnKHerdHigTWM2OCCxZjCzJO69VQ>?M37me|I{QDR2MEO4
SK-MEL-28MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWKxNEDPxE1?M4DRdlczKGh?NVfVUpFYTE2VTx?=M1jWdGlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62LXTybZZmdiCVSz3NSWwuOjhiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjB2MzFOwG0>NGG4OIwzOzh2NECzPC=>
A375P-F11MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTjZlUzOTBizszNNHHNc5g4OiCqNUXNfJNZTE2VTx?=MkPGTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRvZILpeoVvKEF|N{XQMWYyOSClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvODdzIN88US=>NX:3dIpJOjN6NESwN|g>
MALME-3MNET1fndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY\DUYNoOTBizszNM{fLTVczKGh?M1zOV2ROW09?NHfjPJpKSzVyPUGgcm0>NHfEb2szOzh2NECzPC=>
UACC-62Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3mzc|ExKM7:TR?=NGDqTYE4OiCqMmHjSG1UVw>?MnHuTWM2OD1zIH7NMm\5NlM5PDRyM{i=
C32TGM2LNOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml31NVAh|ryPM3\WcFczKGh?NXuzSppuTE2VTx?=MUnJR|UxRTFibl2=MWSyN|g1PDB|OB?=
SK-MEL-1Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV6xNEDPxE1?M17SXlczKGh?NYq3NVBMTE2VTx?=NHPKPWFKSzVyPUKgcm0>NWHjbFlkOjN6NESwN|g>
M14MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjEUXNvOTBizszNNUHseG9JPzJiaB?=M4TpNmROW09?NVHsTmIzUUN3ME2yJI5ONECwd3gzOzh2NECzPC=>
SK-MEL-28M33JdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWqxNEDPxE1?MmDCO|IhcA>?NHzjTnFFVVORM4\2UmlEPTB;MzDuUS=>M3jFU|I{QDR2MEO4
A375NEKzTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYSxNEDPxE1?MkjSO|IhcA>?NUXYUJVkTE2VTx?=MUfJR|UxRTRibl2=NF3YOYwzOzh2NECzPC=>
DU-4475MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3q1b|ExKM7:TR?=MXS3NkBpM2Tmc2ROW09?MmTnTWM2OD13IH7NM4jiNFI{QDR2MEO4
UACC-257NHrMcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrxUG4yOCEQvF2=NEj4ZWw4OiCqM1Txc2ROW09?Mm\VTWM2OD14IH7NMYmyN|g1PDB|OB?=
Colo 205MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkfBNVAh|ryPM1XOdlczKGh?NVPXVVRmTE2VTx?=M2PiXGlEPTB;NzDuUS=>M{ToRlI{QDR2MEO4
SK-MEL-3NWDL[49CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYSxNEDPxE1?NYjuc|NwPzJiaB?=NEPjdYxFVVORNGKzcolKSzVyPUegcm0>NUnCUVFTOjN6NESwN|g>
SH-4NX\3SJZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3IS4pjOTBizszNMoX2O|IhcA>?MUjEUXNQMnPKTWM2OD16IH7NM4PaT|I{QDR2MEO4
A101DNF7vN3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjPOJoyOCEQvF2=MXW3NkBpNVvaTWp[TE2VTx?=NEHScIJKSzVyPUmgcm0>NIjVcYQzOzh2NECzPC=>
ES-2MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnNTlkyOCEQvF2=MkPIO|IhcA>?NH3BWmlFVVORNH[2elZKSzVyPUWzJI5OM4XxOlI{QDR2MEO4
HT-29MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITWfWkyOCEQvF2=NHH3bG84OiCqNEW0UW9FVVORNYjQfHhqUUN3ME22OkBvVQ>?M{OwZVI{QDR2MEO4
SW1417MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2f4XFExKM7:TR?=MWq3NkBpMlPzSG1UVw>?M2PXNGlEPTB;MUW4JI5OMofzNlM5PDRyM{i=
SW872NVTwV3Z3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jPeVExKM7:TR?=MXe3NkBpM3zaNmROW09?MYfJR|UxRTN5NzDuUS=>M3;1fVI{QDR2MEO4
RKOM1f6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVPQbZMzOTBizszNMmHXO|IhcA>?M4HMbmROW09?MkXMTWM2OD1{LkWyNkDPxE1?NIi4[HUzOzh2NECzPC=>
A673M1LWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;lTFExKM7:TR?=MmfVO|IhcA>?Mk\ySG1UVw>?MVPJR|UxRTFyIN88US=>NV\KeJpUOjN6NESwN|g>
GCTNF\qcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUOxNEDPxE1?M4XNOFczKGh?MlGwSG1UVw>?MUPJR|UxRTFyIN88US=>MnqxNlM5PDRyM{i=
WM-115MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXixeo1IOTBizszNMUK3NkBpNEDZSJRFVVORM1PHTmlEPTB;NTDuUS=>NVfPcHN4OjN6NESwN|g>
YUMACNHvQXW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV[xNEDPxE1?M4jZT|czKGh?MWfEUXNQMVPJR|UxRTVibl2=MlPQNlM5PDRyM{i=
OV-90M4nJUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYCxNEDPxE1?MlL5O|IhcA>?NEXFS3hFVVORNXvZRZNPUUN3ME2yPUBvVQ>?NUTmTXlWOjN6NESwN|g>
NCI-H508MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEfOVlAyOCEQvF2=NEfm[FE4OiCqMkXuSG1UVw>?NHjLfXFKSzVyPUGwJO69VQ>?M3roWlI{QDR2MEO4
MDA-MB-231MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3BWXgyOCEQvF2=MknWO|IhcA>?NHq0OGpFVVORNEfUWXlKSzVyPUGwJO69VQ>?MYiyN|g1PDB|OB?=
SW756M{\HTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE[1[lkyOCEQvF2=MlXoO|IhcA>?MVLEUXNQNVrlOWJKUUN3ME2xNEDPxE1?M3HicFI{QDR2MEO4
SW-837M3:3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVGxNEDPxE1?MnTjO|IhcA>?M4faXWROW09?MmjhTWM2OD1zMDFOwG0>NFXDd4EzOzh2NECzPC=>
UMUC-3NUHNNmI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUexNEDPxE1?NUXTUpBpPzJiaB?=NWG1R3l[TE2VTx?=MnjETWM2OD1zMDFOwG0>M4rCTFI{QDR2MEO4
LS-174TNIH5fWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jvc|ExKM7:TR?=NEPFd3A4OiCqNUTGOlVZTE2VTx?=M{KySWlEPTB;MUCg{txOMoW3NlM5PDRyM{i=
A549M2WySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEW2UlUyOCEQvF2=MofCO|IhcA>?NFXaVnhFVVORMmnRTWM2OD1zMDFOwG0>NXrTT|BTOjN6NESwN|g>
SHP-77MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nXS|ExKM7:TR?=NVfaNm13PzJiaB?=MVvEUXNQMV;JR|UxRTFyIN88US=>M4K3VlI{QDR2MEO4
SW480NVzLeYFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mne1NVAh|ryPMV63NkBpMYfEUXNQNX\zOm5[UUN3ME2xNEDPxE1?NG\acowzOzh2NECzPC=>
DLD-1M2L4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITxbo4yOCEQvF2=M4LrOFczKGh?MmXKSG1UVw>?NXrmSnEzUUN3ME2xNEDPxE1?NGX1U3IzOzh2NECzPC=>
HCT-116MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvIXG4yOCEQvF2=NF\lTno4OiCqMV;EUXNQM3nO[GlEPTB;MUCg{txOMYqyN|g1PDB|OB?=
NCI-H747M{nI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkHtNVAh|ryPMWG3NkBpNHn5RWJFVVORMUPJR|UxRTFyIN88US=>MWqyN|g1PDB|OB?=
T-84NU\0[nVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\tdVExKM7:TR?=NHjNS|E4OiCqNF;idI5FVVORNH3sWGVKSzVyPUGwJO69VQ>?MX2yN|g1PDB|OB?=
NCI-H460NWDX[IhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnPNVAh|ryPNGrGfWs4OiCqNUDZN45iTE2VTx?=MXnJR|UxRTFyIN88US=>M4KzdFI{QDR2MEO4
Calu-6MnrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LLWlExKM7:TR?=MnXlO|IhcA>?NUfPXpVGTE2VTx?=NVKyZXBiUUN3ME2xNEDPxE1?MUCyN|g1PDB|OB?=
HCC-2998MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XPZlExKM7:TR?=MX23NkBpM2n2[2ROW09?M3T2dGlEPTB;MUCg{txOM{\DclI{QDR2MEO4
LS1034Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUmxNEDPxE1?MVS3NkBpMXvEUXNQNFzicGlKSzVyPUGwJO69VQ>?M3KxNFI{QDR2MEO4
CHP-212NFrJbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWmxNEDPxE1?M4HsRVczKGh?M{DzcGROW09?NUDITHNXUUN3ME2xNEDPxE1?MUWyN|g1PDB|OB?=
SK-N-ASMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mln2NVAh|ryPMmLxO|IhcA>?NFPD[5ZFVVORM2T0NWlEPTB;MUCg{txOMknRNlM5PDRyM{i=
BFTC-905MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGP2[2kyOCEQvF2=M1GwPVczKGh?NVv5TVFnTE2VTx?=M{H5Z2lEPTB;MUCg{txOM3jvclI{QDR2MEO4
HuT78NWXvPYIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPPNVAh|ryPNUjVSXd6PzJiaB?=M3i0S2ROW09?NVnpPWZUUUN3ME21NkBvVQ>?MnjtNlM5PDRyM{i=
RPMI-8226NVfEXIN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jHcFExKM7:TR?=NFPVOWI4OiCqNEHQcIhFVVORNVHzfJA3UUN3ME2yOlMhdk1?MWiyN|g1PDB|OB?=
BC-3NFS2So5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LPSVExKM7:TR?=NFju[2c4OiCqNW\Y[pFPTE2VTx?=MYXJR|UxRTJ5NzDuUS=>NFPDT5kzOzh2NECzPC=>
ACHNM1TiSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnZNVAh|ryPMXG3NkBpNIjvW2VFVVORMWLJR|UxRTJ7NDDuUS=>NVjMZ2dEOjN6NESwN|g>
JRT3-T35NXXDbGF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjYR3kyOCEQvF2=MXK3NkBpM2DiOWROW09?M1HqZWlEPTB;Mkm1JI5ONELYWXQzOzh2NECzPC=>
SK-MES-1NUfRNXhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPmWZQyOCEQvF2=MX63NkBpNVj3eWxmTE2VTx?=MUjJR|UxRTN{OTDuUS=>NX3TcXVqOjN6NESwN|g>
CESSNEHwOY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3VVpoyOCEQvF2=NEntOIM4OiCqMlTySG1UVw>?MWjJR|UxRTR7NzDuUS=>NWLmXmRSOjN6NESwN|g>
H4MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jlRVExKM7:TR?=NUKxZmNuPzJiaB?=M1LIemROW09?Mn7UTWM2OD14MUmgcm0>M{TXV|I{QDR2MEO4
BC-1MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV70dlFvOTBizszNM3jWVVczKGh?NXPUZ3ZxTE2VTx?=NHrKNFRKSzVyPUewOEBvVQ>?M1TvWVI{QDR2MEO4
DBNWP0UoozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XHclExKM7:TR?=NVrsd|lVPzJiaB?=NGWwfZRFVVORNGK0NHBKSzVyPUi3N{BvVQ>?M2DP[FI{QDR2MEO4
RPMI-6666NXrvTJByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYexNEDPxE1?NUTF[|FUPzJiaB?=MXTEUXNQMWPJR|UxRTl{ODDuUS=>NFLQNJMzOzh2NECzPC=>
MC/CARM3Xmcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEns[ooyOCEQvF2=Mo\6O|IhcA>?NEjMepRFVVORNVq5VZQ3UUN3ME2xMlAxOiEQvF2=NG[yNWEzOzh2NECzPC=>
SNU-1MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DEZ|ExKM7:TR?=M{nrOVczKGh?MVrEUXNQM4XRfWlEPTB;MT61NFEh|ryPM3i1SlI{QDR2MEO4
CEM/C1MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PTelExKM7:TR?=NF\LRoo4OiCqM3;HUmROW09?NWi4OlRQUUN3ME2xMlc4OyEQvF2=MmrSNlM5PDRyM{i=
GDM-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\2c5VoOTBizszNMXu3NkBpNYrvZZp[TE2VTx?=NITpPItKSzVyPUGuPVk4KM7:TR?=MUCyN|g1PDB|OB?=
HT-1080Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWWzT5lIOTBizszNNHq3Rlk4OiCqNVHrV4FkTE2VTx?=MUHJR|UxRTJwMEC0JO69VQ>?MkLWNlM5PDRyM{i=
HL-60NFzXbnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUSxNEDPxE1?NULtXY04PzJiaB?=NVnyWYxLTE2VTx?=M2mxOGlEPTB;Mj6xO|gh|ryPNGPRZWwzOzh2NECzPC=>
C3AM4DoWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlm0NVAh|ryPNEjo[Iw4OiCqMVjEUXNQMXvJR|UxRTVwNEG0JO69VQ>?NVnLeYxiOjN6NESwN|g>
MES-SAMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDkSGoyOCEQvF2=NUDCdJdOPzJiaB?=NXvrdmpPTE2VTx?=MkToTWM2OD14Lkm4PUDPxE1?NYnKWJlEOjN6NESwN|g>
22Rv1NFXVSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEG3ZogyOCEQvF2=MXy3NkBpNVLsN5RwTE2VTx?=NHLwbnlKSzVyPUGwJO69VQ>?MYSyN|g1PDB|OB?=
647-VMlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDkNVAh|ryPNUX5d4lOPzJiaB?=NE\iWIFFVVORMnq1TWM2OD1zMDFOwG0>NHjsOY0zOzh2NECzPC=>
786-ONYPGXlltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkfSNVAh|ryPMnfPO|IhcA>?M{WzUWROW09?NGXnOXpKSzVyPUGwJO69VQ>?NV3KXGJ2OjN6NESwN|g>
A172MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGq0PGIyOCEQvF2=NIjWN4g4OiCqMX3EUXNQNXXKfnVEUUN3ME2xNEDPxE1?MViyN|g1PDB|OB?=
A204NF\HS|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYGxNEDPxE1?NIXzPGw4OiCqNYPoeFE3TE2VTx?=M2LpTGlEPTB;MUCg{txONV;uUnVWOjN6NESwN|g>
A427MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUSxNEDPxE1?NE\qclM4OiCqNXW2cJRvTE2VTx?=M37oZ2lEPTB;MUCg{txONYfJZppyOjN6NESwN|g>
A431MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX[xNEDPxE1?MnTIO|IhcA>?M3S4d2ROW09?MVfJR|UxRTFyIN88US=>MYKyN|g1PDB|OB?=
A2780MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfROmJEOTBizszNM3y4flczKGh?NV;3e5ZWTE2VTx?=NHWyU4NKSzVyPUGwJO69VQ>?M1vl[FI{QDR2MEO4
ARH-77MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF[2OlAyOCEQvF2=NHq0TJY4OiCqNWezSJl2TE2VTx?=NH[2Z4pKSzVyPUGwJO69VQ>?MYqyN|g1PDB|OB?=
Be(2)CMoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfiSoZEOTBizszNM3zxXlczKGh?MXrEUXNQMkXqTWM2OD1zMDFOwG0>NF7C[oEzOzh2NECzPC=>
BT-20NFnrdXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjJNVAh|ryPMnPKO|IhcA>?NYGy[5BWTE2VTx?=MmTETWM2OD1zMDFOwG0>MnPnNlM5PDRyM{i=
BxPc3NED4bpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rZbVExKM7:TR?=MUi3NkBpMl3jSG1UVw>?MVjJR|UxRTFyIN88US=>M{HFXFI{QDR2MEO4
C-4 IM2LORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1f4blExKM7:TR?=MV63NkBpMVfEUXNQMXvJR|UxRTFyIN88US=>MVSyN|g1PDB|OB?=
C33AMn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PKfFExKM7:TR?=MnrRO|IhcA>?M2TZfmROW09?Mo\NTWM2OD1zMDFOwG0>NHnYVoszOzh2NECzPC=>
CAL-27M4q3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HBflExKM7:TR?=NI\mZnk4OiCqMnjQSG1UVw>?NYDB[ZlSUUN3ME2xNEDPxE1?NIK2bJUzOzh2NECzPC=>
CAL-62MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTwN2cyOCEQvF2=M1LCUFczKGh?M{PxdGROW09?M3jQVWlEPTB;MUCg{txOMl\vNlM5PDRyM{i=
Calu-3MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfJ[pNJOTBizszNMVK3NkBpNEPXcmJFVVORM3fGXGlEPTB;MUCg{txONETM[GozOzh2NECzPC=>
CaOV3M3fxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITDWocyOCEQvF2=M3TJSlczKGh?NX3Uc295TE2VTx?=M2D2U2lEPTB;MUCg{txOM4X2bVI{QDR2MEO4
CGTHW1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYOxNEDPxE1?NUK4UGJTPzJiaB?=MkS4SG1UVw>?M13LfGlEPTB;MUCg{txONEC5ZlEzOzh2NECzPC=>
CHL-1MmjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInET5kyOCEQvF2=NX3qNGdSPzJiaB?=NX;Z[Go2TE2VTx?=NY\STXd1UUN3ME2xNEDPxE1?MW[yN|g1PDB|OB?=
Colo320DMNXXZRmx1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml3LNVAh|ryPMkLyO|IhcA>?MVrEUXNQMlrhTWM2OD1zMDFOwG0>M13CNVI{QDR2MEO4
Colo704MlzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlvSNVAh|ryPMYq3NkBpNYPlcINJTE2VTx?=NWDSVm5oUUN3ME2xNEDPxE1?M2fQN|I{QDR2MEO4
COR-L23NXj6dWtST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3mxelExKM7:TR?=M165UFczKGh?NGfmNnRFVVORM{f3VWlEPTB;MUCg{txOM1TU[|I{QDR2MEO4
CRO-AP2NX\UPZZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\4XXMyOCEQvF2=M{nCfVczKGh?NGrQdYdFVVORM3XFWWlEPTB;MUCg{txONHHHSXYzOzh2NECzPC=>
DaudiNHmxfoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHMOZoyOCEQvF2=M3XlS|czKGh?MVTEUXNQMVHJR|UxRTFyIN88US=>NETsNnAzOzh2NECzPC=>
DOTC 24510M37oXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX[0ZYFQOTBizszNNHuyTno4OiCqM3mwOmROW09?MUDJR|UxRTFyIN88US=>NH;QdYIzOzh2NECzPC=>
DU-145MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\adWQ5OTBizszNNHLwfHI4OiCqMl3WSG1UVw>?MUfJR|UxRTFyIN88US=>NXfwUIs3OjN6NESwN|g>
EB-3NYjxd2p{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jVNVExKM7:TR?=MmHHO|IhcA>?NFzv[JdFVVORMVzJR|UxRTFyIN88US=>NHTROoYzOzh2NECzPC=>
EFM-19MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zwe|ExKM7:TR?=Mn36O|IhcA>?NYjQUlByTE2VTx?=MUDJR|UxRTFyIN88US=>NHnFXIkzOzh2NECzPC=>
EKVXM4\jZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7L[3EyOCEQvF2=MU[3NkBpMULEUXNQNXjNOG9MUUN3ME2xNEDPxE1?M2e3TFI{QDR2MEO4
FaDuMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUntTnlzOTBizszNNWjkZ2lQPzJiaB?=M175SGROW09?MoexTWM2OD1zMDFOwG0>MojoNlM5PDRyM{i=
G401MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfuVFAyOCEQvF2=MkPlO|IhcA>?M4DSS2ROW09?M4PCZWlEPTB;MUCg{txOMoTNNlM5PDRyM{i=
HCC-70NFvBcmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYTSfoM3OTBizszNMWS3NkBpNUHIbY8{TE2VTx?=NVT4UWZVUUN3ME2xNEDPxE1?MXGyN|g1PDB|OB?=
HCC-1954M3S0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\aeVExKM7:TR?=NFr3cIw4OiCqNGXV[YlFVVORMX7JR|UxRTFyIN88US=>MmnwNlM5PDRyM{i=
HelaM{ThSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEezSWYyOCEQvF2=MXm3NkBpNWXi[3N[TE2VTx?=MYPJR|UxRTFyIN88US=>M3LFTlI{QDR2MEO4
Hep3BMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVGxNEDPxE1?NXHycppzPzJiaB?=MYrEUXNQMojzTWM2OD1zMDFOwG0>MmfiNlM5PDRyM{i=
HMCBNV[4RphGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3TDTlExKM7:TR?=MV[3NkBpM3vaNGROW09?MX3JR|UxRTFyIN88US=>NVnUdmhCOjN6NESwN|g>
HN5MlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLrPGl[OTBizszNM2LsUVczKGh?NWDkcYFiTE2VTx?=M2ThUGlEPTB;MUCg{txOMXuyN|g1PDB|OB?=
HOSNIPZbmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HDSlExKM7:TR?=NIfHSpA4OiCqMWHEUXNQNV;4bXBsUUN3ME2xNEDPxE1?NGXncIkzOzh2NECzPC=>
HPAF-IIMlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUH4d25nOTBizszNNGjU[lk4OiCqNEnPe2tFVVORMVHJR|UxRTFyIN88US=>NXzmUYFROjN6NESwN|g>
Hs746.TNYDR[WtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjuNVAh|ryPM4fHclczKGh?MUfEUXNQMoXDTWM2OD1zMDFOwG0>MU[yN|g1PDB|OB?=
HTMkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnixNVAh|ryPMVy3NkBpM1LGZWROW09?M{PvZ2lEPTB;MUCg{txONHq4SXIzOzh2NECzPC=>
HT-3NYThfYhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLndHgyOCEQvF2=NFflZWw4OiCqMk\5SG1UVw>?NXLkOmtRUUN3ME2xNEDPxE1?MkHxNlM5PDRyM{i=
HuNS-1NX3lfZBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU[xNEDPxE1?MX:3NkBpNF3Pd3hFVVORM4LkUGlEPTB;MUCg{txOMXeyN|g1PDB|OB?=
IGROV1MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jqb|ExKM7:TR?=MVW3NkBpM3T3fWROW09?M{npVmlEPTB;MUCg{txOMkn3NlM5PDRyM{i=
J82M1TEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTWPZgyOCEQvF2=MlTsO|IhcA>?NFPWeWVFVVORNH65PYVKSzVyPUGwJO69VQ>?M1e2TFI{QDR2MEO4
JM1M{LJXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\2dXdMOTBizszNNHrib5Q4OiCqM3zqTmROW09?M2fGdWlEPTB;MUCg{txOMVSyN|g1PDB|OB?=
Kato IIIM3PyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY[xNEDPxE1?NFXMV3Q4OiCqMnHiSG1UVw>?M2fLRmlEPTB;MUCg{txOM4PNdlI{QDR2MEO4
KHOS-240SNYrCepZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3e5UFExKM7:TR?=M332S|czKGh?NFzxZ3JFVVORNWfDXJhUUUN3ME2xNEDPxE1?M4DmZVI{QDR2MEO4
KM-12MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVWxNEDPxE1?NVLyRZVbPzJiaB?=MXTEUXNQNFXRbmlKSzVyPUGwJO69VQ>?M3XXb|I{QDR2MEO4
KPL-1NH\aUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrsNmV4OTBizszNNGfiXZU4OiCqMUjEUXNQNVXJZmZmUUN3ME2xNEDPxE1?MVuyN|g1PDB|OB?=
KYSE-30MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rx[|ExKM7:TR?=MVK3NkBpNVrrSXN7TE2VTx?=MkPsTWM2OD1zMDFOwG0>NH:1bIQzOzh2NECzPC=>
LNCaPMnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfOOnZXOTBizszNMUS3NkBpNX;Lb|BbTE2VTx?=M{eybWlEPTB;MUCg{txOM3voTVI{QDR2MEO4
MCF-7MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXexNEDPxE1?MkPtO|IhcA>?MVzEUXNQNEDrXXNKSzVyPUGwJO69VQ>?M1j6N|I{QDR2MEO4
MC-IXCMlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXLelU5OTBizszNM2[2elczKGh?MW\EUXNQNXe1eJJSUUN3ME2xNEDPxE1?M1fqdVI{QDR2MEO4
MDA-MB-175 VIINGD1OHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfGNVAh|ryPMVG3NkBpNHjmdIZFVVORNWj5[nFvUUN3ME2xNEDPxE1?NYTucGNmOjN6NESwN|g>
MDA-MB-468M2nWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPxNVAh|ryPMXK3NkBpM4fXV2ROW09?NUHxU5ZuUUN3ME2xNEDPxE1?MmrXNlM5PDRyM{i=
MiaPaCaMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;mSFExKM7:TR?=Mn;SO|IhcA>?NIHGOpBFVVORMVjJR|UxRTFyIN88US=>NF6wfJgzOzh2NECzPC=>
Molt-4MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4P4TVExKM7:TR?=NX3WWJlJPzJiaB?=NWLS[WM3TE2VTx?=MmjTTWM2OD1zMDFOwG0>NULNRpJFOjN6NESwN|g>
NCI-ADR/RESNITXWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TsSVExKM7:TR?=NIrOe|M4OiCqMWPEUXNQNXrBc25qUUN3ME2xNEDPxE1?NV3rPWdKOjN6NESwN|g>
NCI-H69MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LwSlExKM7:TR?=NHTacmg4OiCqMYHEUXNQMlLzTWM2OD1zMDFOwG0>NHXOemUzOzh2NECzPC=>
NCI-H82NFzS[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfjNVAh|ryPNYXifVV3PzJiaB?=NFrmPIhFVVORNX6xTmllUUN3ME2xNEDPxE1?MmjVNlM5PDRyM{i=
NCI-N87NGXPOYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\CNVAh|ryPNVr4RnpFPzJiaB?=MoDHSG1UVw>?MmL6TWM2OD1zMDFOwG0>NWHIWWRKOjN6NESwN|g>
NCI-H146NHLTT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljMNVAh|ryPNYi5Tng2PzJiaB?=M4\oTGROW09?M1T2UWlEPTB;MUCg{txONHiyUpUzOzh2NECzPC=>
NCI-H157MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHGNVAh|ryPMXK3NkBpM4jrUWROW09?MnvOTWM2OD1zMDFOwG0>M4LLUFI{QDR2MEO4
NCI-H187M4r2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPSclQyOCEQvF2=MlTaO|IhcA>?NGPrfndFVVORMXrJR|UxRTFyIN88US=>NH3PdoIzOzh2NECzPC=>
NCI-H209MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vuTFExKM7:TR?=M3v1fFczKGh?NUTRS2h5TE2VTx?=M{\3PWlEPTB;MUCg{txONVziUWtKOjN6NESwN|g>
NCI-H226NUixOm9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXqxNEDPxE1?M2jQOlczKGh?NE\NVWRFVVORNX3yRXprUUN3ME2xNEDPxE1?MnrwNlM5PDRyM{i=
NCI-H292MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mmr5NVAh|ryPM3y5SFczKGh?Mn;5SG1UVw>?MWrJR|UxRTFyIN88US=>NVfOUnJWOjN6NESwN|g>
NCI-H322MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjKUnlNOTBizszNM1XzNFczKGh?M1TCemROW09?MVXJR|UxRTFyIN88US=>M{PNeVI{QDR2MEO4
NCI-H358NH;TZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDRNVAh|ryPNHLncXU4OiCqNUXnVIpKTE2VTx?=M{jNNWlEPTB;MUCg{txOMny3NlM5PDRyM{i=
NCI-H520NIfhdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUCxNEDPxE1?M4\meVczKGh?Mo\oSG1UVw>?NEPZRYVKSzVyPUGwJO69VQ>?NVXaSnZ2OjN6NESwN|g>
NCI-H526MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3naTVExKM7:TR?=NUHrSFczPzJiaB?=M{nqcWROW09?NHnEb3RKSzVyPUGwJO69VQ>?MYSyN|g1PDB|OB?=
NCI-H630MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TD[VExKM7:TR?=NV3vN2J4PzJiaB?=M1;qNmROW09?MVvJR|UxRTFyIN88US=>MYSyN|g1PDB|OB?=
NCI-H661Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXyxNEDPxE1?MoLCO|IhcA>?MYrEUXNQNWPGWod5UUN3ME2xNEDPxE1?M4LjNVI{QDR2MEO4
NCI-H716NXn1U3ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zvRlExKM7:TR?=MX23NkBpNHXae5BFVVORMWrJR|UxRTFyIN88US=>MmXzNlM5PDRyM{i=
NCI-H1563NGHFfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LaXlExKM7:TR?=NYPud4VOPzJiaB?=NGTqRpZFVVORM{DqRmlEPTB;MUCg{txOMVGyN|g1PDB|OB?=
NCI-H1792NFy4O2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYD4[I5bOTBizszNNUPG[JE5PzJiaB?=NGDwPW1FVVORNETkSW5KSzVyPUGwJO69VQ>?M2fIV|I{QDR2MEO4
NCI-H2030M13mNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\YXGE4OTBizszNMlPKO|IhcA>?NUjOPYxxTE2VTx?=NFm0O3FKSzVyPUGwJO69VQ>?NGPiPHkzOzh2NECzPC=>
NCI-H2052M3LO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PkbFExKM7:TR?=M2fvNFczKGh?MofXSG1UVw>?NIjHO25KSzVyPUGwJO69VQ>?Ml7wNlM5PDRyM{i=
NCI-H2122MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFO3PHkyOCEQvF2=MUW3NkBpNULse2lnTE2VTx?=M{T2W2lEPTB;MUCg{txOMl\FNlM5PDRyM{i=
NCI-H2228NXrQNWtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojLNVAh|ryPM3TLVlczKGh?NYnNOnYzTE2VTx?=Mn7XTWM2OD1zMDFOwG0>NUPReJF3OjN6NESwN|g>
OE-19MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUXmfoRLOTBizszNNWL2ZW51PzJiaB?=Mon1SG1UVw>?Mk[4TWM2OD1zMDFOwG0>M{ntSFI{QDR2MEO4
OE-21NF\BVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HuTVExKM7:TR?=MlvwO|IhcA>?NESzcIFFVVORNGS3PGdKSzVyPUGwJO69VQ>?M3vpOVI{QDR2MEO4
OE-33NVrSTJBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPUT2MyOCEQvF2=M1n5U|czKGh?MVfEUXNQNVX3UpBSUUN3ME2xNEDPxE1?M3ftVFI{QDR2MEO4
OVCAR-3NGP6PGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfSfVcyOCEQvF2=NIjnNlk4OiCqMWPEUXNQMYXJR|UxRTFyIN88US=>M{nBZ|I{QDR2MEO4
OVCAR-4NV\SeW1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmSzNVAh|ryPNYXFWHhGPzJiaB?=M3;Ub2ROW09?MU\JR|UxRTFyIN88US=>Mn;QNlM5PDRyM{i=
OVCAR-5NXW3N|N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3u2SVExKM7:TR?=M3TkeFczKGh?NWD0TGp2TE2VTx?=MmLhTWM2OD1zMDFOwG0>Mn;LNlM5PDRyM{i=
P3HR-1MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUTuUG9LOTBizszNNFnIXVY4OiCqMnz4SG1UVw>?NETxcoRKSzVyPUGwJO69VQ>?M1PVUVI{QDR2MEO4
PC-3M1fqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUixNEDPxE1?M1vv[lczKGh?NIXZOWFFVVORNWnmUWhxUUN3ME2xNEDPxE1?NWHxdmV4OjN6NESwN|g>
RajiMnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEL1SIQyOCEQvF2=MXS3NkBpM4C5RmROW09?MkjZTWM2OD1zMDFOwG0>MnPTNlM5PDRyM{i=
RDMlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;1NVAh|ryPMYG3NkBpM{nC[WROW09?MlrvTWM2OD1zMDFOwG0>M3[4XlI{QDR2MEO4
RD-ESMnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXuxNEDPxE1?MWG3NkBpNYHYeYd3TE2VTx?=NEH1TGFKSzVyPUGwJO69VQ>?NWDJUJBiOjN6NESwN|g>
RLMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDUNVAh|ryPMWK3NkBpMmfBSG1UVw>?M3jNfGlEPTB;MUCg{txOMVSyN|g1PDB|OB?=
SaOS2MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DzbFExKM7:TR?=NFTMV4k4OiCqNV;VdpRkTE2VTx?=NXH5XmdvUUN3ME2xNEDPxE1?MYGyN|g1PDB|OB?=
SCC-9M2ruO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXexNEDPxE1?MmfxO|IhcA>?MYTEUXNQNFi0eYNKSzVyPUGwJO69VQ>?Mk\1NlM5PDRyM{i=
SCC-12M3j2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3XS5QyOCEQvF2=M3LVblczKGh?M{i3[GROW09?M2LsV2lEPTB;MUCg{txOMXyyN|g1PDB|OB?=
SCC-13MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\vNVAh|ryPNUDofI15PzJiaB?=Ml7TSG1UVw>?MWPJR|UxRTFyIN88US=>M2jVU|I{QDR2MEO4
SCC-15MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\hNVAh|ryPMXi3NkBpNFLMZYZFVVORM{jacWlEPTB;MUCg{txONWrWPIVSOjN6NESwN|g>
SCC-25M2nuc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTId3VXOTBizszNM4XCN|czKGh?MmHKSG1UVw>?M3HCS2lEPTB;MUCg{txOMnKyNlM5PDRyM{i=
SCLC-3MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYqxNEDPxE1?NIjJUYw4OiCqMn3NSG1UVw>?M1K5WGlEPTB;MUCg{txOM4Xmc|I{QDR2MEO4
SF-268MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LOeFExKM7:TR?=NHzXb244OiCqMV7EUXNQNXT6T3kyUUN3ME2xNEDPxE1?Mme1NlM5PDRyM{i=
SF-295M4P4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWn2VpF{OTBizszNMnK3O|IhcA>?M3e0OWROW09?NInkTVZKSzVyPUGwJO69VQ>?NHL1U5kzOzh2NECzPC=>
SJRH30MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfkS5pOOTBizszNMYK3NkBpMUTEUXNQNX\5TWpPUUN3ME2xNEDPxE1?MnX0NlM5PDRyM{i=
SK-BR-3NHq4W|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVKxNEDPxE1?MnTvO|IhcA>?NUS1XZNvTE2VTx?=NXjBcotbUUN3ME2xNEDPxE1?MVGyN|g1PDB|OB?=
SK-LMS-1M{LSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUWxNEDPxE1?M2e1Z|czKGh?NILrO2JFVVORM2OyTmlEPTB;MUCg{txOM3PsfVI{QDR2MEO4
SK-N-DZM1fhWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoK5NVAh|ryPM2i0XFczKGh?NEP3d25FVVORM1LQOGlEPTB;MUCg{txOMmnDNlM5PDRyM{i=
SK-N-F1NGTMRodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLDeYJHOTBizszNMUW3NkBpM{jhZ2ROW09?MorXTWM2OD1zMDFOwG0>NHH5WVAzOzh2NECzPC=>
SKOV-3MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXYNVAh|ryPM4i3cVczKGh?NUfqdpdCTE2VTx?=NHvRN3dKSzVyPUGwJO69VQ>?M4K5U|I{QDR2MEO4
SK-UT-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY[xNEDPxE1?M1;1SVczKGh?M1nycGROW09?MYjJR|UxRTFyIN88US=>NGHYTZIzOzh2NECzPC=>
SN12CMo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUexNEDPxE1?MmftO|IhcA>?M1K5fGROW09?MkD1TWM2OD1zMDFOwG0>M1jKRlI{QDR2MEO4
SNB-19M{H6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\wNVAh|ryPMYW3NkBpM33hU2ROW09?M2PGVmlEPTB;MUCg{txOMorWNlM5PDRyM{i=
SNU-5NYi1dI5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nHSFExKM7:TR?=Mo[3O|IhcA>?NGrlTXVFVVORMmnkTWM2OD1zMDFOwG0>MnLTNlM5PDRyM{i=
SNU-16MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHraRmUyOCEQvF2=M{D4O|czKGh?M1LHOGROW09?MnfaTWM2OD1zMDFOwG0>MkToNlM5PDRyM{i=
SNU-398NXr5cndlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYGxNEDPxE1?M3nFWlczKGh?NE\YcVdFVVORM2G2S2lEPTB;MUCg{txONWi5OmF7OjN6NESwN|g>
SNU-449MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\RbYcyOCEQvF2=M2LQPFczKGh?MkX6SG1UVw>?NEXVU5RKSzVyPUGwJO69VQ>?M4fORlI{QDR2MEO4
SRNYTBXZR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV[xNEDPxE1?MlSwO|IhcA>?MV3EUXNQNITm[lZKSzVyPUGwJO69VQ>?M4PWTVI{QDR2MEO4
ST486NXTYXFJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUXPOlZoOTBizszNNFraS4c4OiCqNEHjO2NFVVORM2Tx[mlEPTB;MUCg{txONV;xboxlOjN6NESwN|g>
SW579MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYGxNEDPxE1?M4TndlczKGh?NIX0[5FFVVORMlHMTWM2OD1zMDFOwG0>M1jiXVI{QDR2MEO4
SW684MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWGxNEDPxE1?NHXvbWg4OiCqMYTEUXNQM2rRXmlEPTB;MUCg{txOMUiyN|g1PDB|OB?=
SW-780MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWG0NINiOTBizszNNIrVd4c4OiCqMYfEUXNQM1fhO2lEPTB;MUCg{txONF7FbIczOzh2NECzPC=>
SW900NVm5OpB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn6yNVAh|ryPNHTQSpM4OiCqNYC2NWFyTE2VTx?=NF2x[mlKSzVyPUGwJO69VQ>?NH:5[lAzOzh2NECzPC=>
SW1088NILDXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVqxNEDPxE1?MkTEO|IhcA>?MWfEUXNQNXn5enlnUUN3ME2xNEDPxE1?MnXKNlM5PDRyM{i=
SW1463NFXNO4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoPkNVAh|ryPMX63NkBpNWPmN5dnTE2VTx?=MXnJR|UxRTFyIN88US=>M{f6fFI{QDR2MEO4
SW1990NWr6ZnZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWSxNEDPxE1?NHLNcXg4OiCqM4XWd2ROW09?MmP5TWM2OD1zMDFOwG0>NV72NFB5OjN6NESwN|g>
T47DM2XnVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{i5S|ExKM7:TR?=NWTPSIxiPzJiaB?=MVTEUXNQMonKTWM2OD1zMDFOwG0>NGf6R3IzOzh2NECzPC=>
TE381.TM37lRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrBfXIyOCEQvF2=MVG3NkBpNITnW4hFVVORMWnJR|UxRTFyIN88US=>MWSyN|g1PDB|OB?=
TK-10MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfZNVAh|ryPMW[3NkBpNY\6eXNyTE2VTx?=MYLJR|UxRTFyIN88US=>NVGzNoZIOjN6NESwN|g>
U2OSNYHCemxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPpNVAh|ryPNXPxdodHPzJiaB?=NUTwSFJVTE2VTx?=Mli5TWM2OD1zMDFOwG0>MUSyN|g1PDB|OB?=
U251NYPNT|I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXreXcyOCEQvF2=NELHe3k4OiCqM1;3UWROW09?NGTKc4tKSzVyPUGwJO69VQ>?MW[yN|g1PDB|OB?=
UACC-812NIHNNHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYTqTHgzOTBizszNNG\kZ2M4OiCqMYjEUXNQMWfJR|UxRTFyIN88US=>NE\0W28zOzh2NECzPC=>
YAPCMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVLOcHV1OTBizszNMoTkO|IhcA>?M1njeGROW09?NVr5fI9DUUN3ME2xNEDPxE1?NVzueJhUOjN6NESwN|g>
ZR-75-1M1i4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PMZVExKM7:TR?=MWW3NkBpMkXYSG1UVw>?NUDRR3Y6UUN3ME2xNEDPxE1?Mo[yNlM5PDRyM{i=
A375MVjGeY5kfGmxbjDhd5NigQ>?NX;iO|k3OS5{IN88US=>M2\RfFQhcA>?M1jYfmROW09?MmTqTY5pcWKrdHnvckBw\iCyaH;zdIhwenmuYYTpc44hd2ZiTVXLMEBGWktuIHHu[EBUPlB?NXTPV3htOjJ|OEm0O|E>
YUSIT1NF;oe2NHfW6ldHnvckBie3OjeR?=M{PKUmROW09?M2nnbJJm\HWlZXSgd4Vve2m2aY\peJkhf2m2aDDJR|UxKD5iMD61JO69VQ>?NGD4cJQzOjN6OUS3NS=>
MeWoM33Ncmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7MV3EUXNQM1\vUWlEPTBiPTC5PFchdk1?NVvQS4ZLOjZyMUi1NlQ>
WiDrNEH2b29Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=MXLEUXNQNXjCNW1wUUN3MDC9JFc3KG6PM2rqeVI3ODF6NUK0
Colo-205MWXGeY5kfGmxbjDhd5NigQ>?MkjhNUDPxE1?NYKwNGJUPCCmMUHEUXNQM4LlfWlv\HWlZXSgZUBpcWeqbImgZ49ueGG{YXLs[UBkd22yYXP0bY9vKHCqZX7veJlx\Q>?M3TKcVI2OzhzMUWy
RBW-1NFv0ephHfW6ldHnvckBie3OjeR?=MXmxJO69VQ>?MoXOSG1UVw>?MmTCUo8hemWmdXP0bY9vKG:oIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9vMYOyOFg5PTZ7MB?=
RBO-1M2j2cGZ2dmO2aX;uJIF{e2G7M3jzVlEh|ryPMYHEUXNQM1jGXGlvcGmkaYTpc44hd2ZiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44>MkPNNlQ5QDV4OUC=
RBO-2MX7GeY5kfGmxbjDhd5NigQ>?NYGy[HBZOSEQvF2=MXzEUXNQNHHqTJRKdmirYnn0bY9vKG:oIDDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>?MUGyOFg5PTZ7MB?=
RBOWM1zCbmZ2dmO2aX;uJIF{e2G7M{D5dVEh|ryPMY\EUXNQNXjw[HpzUW6qaXLpeIlwdiCxZjCgUYVsKDFxMjDwbI9{eGixconsZZRqd25?M4Tqb|I1QDh3Nkmw
M257MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4fKSFExOCCwTR?=NV3TfYJDPzJiaB?=Ml2xSI9meyCwb4SgbY5pcWKrdDDwdo9tcW[ncnH0bY9vKG:oIF2yOVch[2WubDDoZZJjd3W{aX7nJJdqdGRidInw[UBDWkGIM4jyUlI{OzF5NES2
LCPM37mOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\6dXkyODBibl2=NUPoOJlOPzJiaB?=M{niZ2lvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCOQ2CgZ4VtdCCqYYLic5VzcW6pIFLSRWYhXjZyMGKgcZV1[W62YYTpc44>NXS3coVMOjN|MUe0OFY>
WM266MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3QNVAxKG6PM4rDSVczKGh?NGj6UZhKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44hd2ZiV12yOlYh[2WubDDoZZJjd3W{aX7nJGJTSUZiVk[wNWQhdXW2YX70ZZRqd25?NWrie2FqOjN|MUe0OFY>
M257M1fOXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHWU2syODBibl2=NHLLVGo4OiCqNUnXWnhKTG:nczDuc5QhcW6qaXLpeEBGWktzLUKgdIhwe3Cqb4L5cIF1cW:wIHnuJG0zPTdiY3XscEBp[XKkb4XybY5oKHerbHSgeJlx\SCEUlHGMXuyN|MyPzR2Nh?=
LCPNWiyN2tMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1GyNlExOCCwTR?=NFrXUJY4OiCqMWTJcohq[mm2IFXST|EuOiCyaH;zdIhwenmuYYTpc44hcW5iTFPQJINmdGxiaHHyZo92emmwZzDCVmFHKFZ4MEDSJI12fGGwdHH0bY9vMX:yN|MyPzR2Nh?=
WM266NGPCbVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXWxNFAhdk1?MV:3NkBpNWTFdWo4UW6qaXLpeEBGWktzLUKgdIhwe3Cqb4L5cIF1cW:wIHnuJHdOOjZ4IHPlcIwhcGG{Yn;1dolv\yCEUlHGJHY3ODCGIH31eIFvfGG2aX;uMl;ZNlM{OTd2NE[=

... Click to View More Cell Line Experimental Data

In vivo Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. [1]
Features

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Sylvie Laquerre, et al. 2009, EORTC International Conference. Abst B88.

[2] Greger JG, et al. Mol Cancer Ther, 2012, 11(4), 909-920.

Chemical Information

Download Dabrafenib (GSK2118436) SDF
Molecular Weight (MW) 519.56
Formula

C23H20F3N5O2S2

CAS No. 1195765-45-7
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 30 mg/mL (57.74 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol 8 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide

Customer Product Validation (4)


Click to enlarge
Rating
Source J Clin Invest 2014 24(3), 1406-17. Dabrafenib (GSK2118436) purchased from Selleck
Method Western blot
Cell Lines A375P cells
Concentrations 10 uM
Incubation Time 48 h
Results GSK2118436 inhibition produced an additive increase in LC3II/LC3I ratio, but the combination of GSK2118436 with HCQ produced substantial increases in LC3II/LC3I ratio and p62 levels, and the triple drug combination (GSK2118436, GSK1120212, and HCQ) produced the most substantial increase in LC3II/LC3I ratio and buildup of p62, indicative of simultaneous autophagy induction and distal autophagy blockade.

Click to enlarge
Rating
Source J Clin Invest 2014 124(11), 5074-84. Dabrafenib (GSK2118436) purchased from Selleck
Method Western blot
Cell Lines CLL cells
Concentrations 6 uM
Incubation Time 24 h
Results Levels of phosphorylated ERK (pERK) and total ERK (tERK) in enriched CD19+CD5+ CLL cells or CD14+ monocytes were measured by Western blot analysis. CLL cells exposed to dabrafenib or vemurafenib had an elevated pERK/tERK ratio as compared with vehicle(Left). The quantitative results had shown in right(P < 0.01).

Click to enlarge
Rating
Source Transl Res 2014 10.1016/j.trsl.2014.06.005. Dabrafenib (GSK2118436) purchased from Selleck
Method MTT assay
Cell Lines FRO and SW1736 cells
Concentrations 0-5 uM
Incubation Time 72 h
Results Dabrafenib showed inhibition of cell growth with concentrations between 0.5 and 5 uM.

Click to enlarge
Rating
Source Cell Death Dis 2014 5, e1278. Dabrafenib (GSK2118436) purchased from Selleck
Method TUNEL staining
Cell Lines C57Bl/6J mice
Concentrations 100/300 mg/kg
Incubation Time 1 h
Results Dabrafenib protects mice from acetaminophen-induced hepatotoxicity.The pretreatment of mice with dabrafenib (100 mg/kg or 300 mg/kg) apparently eased the acetaminophen-caused liver injury.

Product Use Citation (10)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Raf Products

  • LY3009120

    LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.

  • GDC-0994

    GDC-0994 is a potent, orally available ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.

  • Ulixertinib (BVD-523, VRT752271)

    Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.

  • Vemurafenib (PLX4032, RG7204)

    Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM in cell-free assay.

    Features:A novel and potent inhibitor of the B-RAFV600E oncoprotein.

  • Sorafenib

    Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

  • Sorafenib Tosylate

    Sorafenib Tosylate is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

  • PLX-4720

    PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.

  • TAK-632

    TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.

  • GDC-0879

    GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.

  • GW5074

    GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted.

Recently Viewed Items

Tags: buy Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) ic50 | Dabrafenib (GSK2118436) price | Dabrafenib (GSK2118436) cost | Dabrafenib (GSK2118436) solubility dmso | Dabrafenib (GSK2118436) purchase | Dabrafenib (GSK2118436) manufacturer | Dabrafenib (GSK2118436) research buy | Dabrafenib (GSK2118436) order | Dabrafenib (GSK2118436) mouse | Dabrafenib (GSK2118436) chemical structure | Dabrafenib (GSK2118436) mw | Dabrafenib (GSK2118436) molecular weight | Dabrafenib (GSK2118436) datasheet | Dabrafenib (GSK2118436) supplier | Dabrafenib (GSK2118436) in vitro | Dabrafenib (GSK2118436) cell line | Dabrafenib (GSK2118436) concentration | Dabrafenib (GSK2118436) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us